| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 05/03/2007 | WO2007048595A1 Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses |
| 05/03/2007 | WO2007048413A1 IMPLANTABLE BIOCOMPATIBLE IMMtTNOISOLATORY VEHICLE FOR DELIVERY OF GDNF |
| 05/03/2007 | WO2007048356A1 Pharmaceutical composition based on plant extracts for the treatment and/or prevention of migraines |
| 05/03/2007 | WO2007032936A3 Azafused cyclin dependent kinase inhibitors |
| 05/03/2007 | WO2007030939A3 Methods of modulating neurotrophin-mediated activity |
| 05/03/2007 | WO2007030697A3 Modulation of neurogenesis by hdac inhibition |
| 05/03/2007 | WO2007028821A3 Treatment of autoimmune diseases |
| 05/03/2007 | WO2007026219A3 Combinations of a 5-ht1b antagonist with a noradrenalin re-uptake inhibitor or a serotonin noradrenalin reutake inhibitor for treating cns conditions |
| 05/03/2007 | WO2007022947A3 5-ring heteroaromatic compounds and their use as binding partners for 5-ht5 receptors |
| 05/03/2007 | WO2007022535A3 Prodrugs of active agents |
| 05/03/2007 | WO2007022416A3 Single chain antibodies against beta-amyloid peptide |
| 05/03/2007 | WO2007021982A3 Modulators of cystic fibrosis transmembrane conductance regulator |
| 05/03/2007 | WO2007021711A3 Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands |
| 05/03/2007 | WO2007018998A3 Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators |
| 05/03/2007 | WO2007013936A3 Method for treating nervous system disorders and conditions |
| 05/03/2007 | WO2007009462A3 Treatment of migraine and headaches |
| 05/03/2007 | WO2007003767A3 Novel chemical compounds and the uses thereof as a medicine |
| 05/03/2007 | WO2006138127A3 Botulinum toxin and the treatment of primary disorders of mood and affect |
| 05/03/2007 | WO2006123257A3 Phenyl-3-{(3-(1h-pyrrol-2-yl)-[1, 2 , 4]0xadiaz0l-5-yl]piperidin-1-yl}-methanone derivatives and related compounds as positive allosteric modulators of metabotropic glutamate receptors |
| 05/03/2007 | WO2006106432A3 4-arylpiperidine derivatives and use thereof for preparing a medicament for the treatment of cns disorders |
| 05/03/2007 | WO2006096640A3 Use of neuronal precursor cells for treatment of central nervous system lesions |
| 05/03/2007 | WO2006081779A3 A pharmaceutical composition containing olanzapine as the active agent and a process for the preparation thereof |
| 05/03/2007 | WO2006073714A3 Use of certain phenyl-naphthyl compounds that do not have significant affintiy to er alpha or beta for protection of neurons and oligodendrocytes in the treatment of multiple sclerosis |
| 05/03/2007 | WO2005094896A3 Targeted serotonin reuptake inhibitors |
| 05/03/2007 | US20070101450 DNA that encodes a protein having high-affinity choline transporter activity |
| 05/03/2007 | US20070100001 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof |
| 05/03/2007 | US20070099991 Selective rxr ligands |
| 05/03/2007 | US20070099990 N-(3-(p-Isopropylphenyl)-4,6,7-trimethyl-2,3-dihydro-1-benzofuran-5-yl)-3,3-dimethylbutanamide or a salt thereof; cerebrovascular disorders |
| 05/03/2007 | US20070099981 Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands |
| 05/03/2007 | US20070099980 Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands |
| 05/03/2007 | US20070099977 Conjugated psychotropic drugs and uses thereof |
| 05/03/2007 | US20070099975 Imidazole derivatives modulating the sodium channels |
| 05/03/2007 | US20070099957 Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof |
| 05/03/2007 | US20070099956 Nitrogen-containing heterocyclic derivatives having 2, 6-disubstituted styryl |
| 05/03/2007 | US20070099933 Indole derivatives as serotonin reuptake inhibitors |
| 05/03/2007 | US20070099921 Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 05/03/2007 | US20070099914 Piperidine Derivatives |
| 05/03/2007 | US20070099909 N-(2-arylethyl)benzylamines as antagonists of the 5-ht6 receptor |
| 05/03/2007 | US20070099904 Pharmaceutical composition for the treatment of cns and other disorders |
| 05/03/2007 | US20070099899 Heterocyclic dihydropyrimidine compounds |
| 05/03/2007 | US20070099892 Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging |
| 05/03/2007 | US20070099878 Use of porphyrin synthesis substances for carrying out phototherapy and for curing skin and articulation diseases |
| 05/03/2007 | US20070099863 Compounds for the treatment of demyelinating and autoimmune diseases |
| 05/03/2007 | US20070099849 Co-Therapy for the Treatment of Migraine Comprising Anticonvulsant Derivatives and Anti-Migraine Agents |
| 05/03/2007 | US20070099846 Administering or applying anserine for treating muscle spasm, localized swelling, inflammation, joint pains, muscle fatigue, stress and myocardial infarction optionally with a diuretic |
| 05/03/2007 | US20070099270 Novel neurotrophic factors |
| 05/03/2007 | US20070098807 Matrices for drug delivery and methods for making and using the same |
| 05/03/2007 | US20070098793 Oxymorphone controlled release formulations |
| 05/03/2007 | US20070098792 Oxymorphone controlled release formulations |
| 05/03/2007 | US20070098777 Pharmaceutical or Food Composition for Treatment or Prevention of Brain Edema |
| 05/03/2007 | US20070098736 Injection vehicle for polymer-based formulations |
| 05/03/2007 | US20070098734 loading antigen presenting cells from a subject; loading antigen presenting cells (APC's) having Class I MHC (major histocompatibility factor) molecules with T cell epitopes; culturing CD8+ T cells with APC's; expanding in culture; for allergic asthma, insulin dependent diabetes, arthritis |
| 05/03/2007 | US20070098701 administering galectins to the brain of the vertebrates to intensify in vivo proliferation of subventricular zone astrocytes and neuron stem cells; treatment of neurodegenerative diseases, brain and nervous system disorders |
| 05/03/2007 | US20070098634 method of inhibiting the growth; inhibiting neoplastic cell growth; cancer |
| 05/03/2007 | CA2628074A1 Aminodihydrothiazine derivative |
| 05/03/2007 | CA2627653A1 Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists |
| 05/03/2007 | CA2627640A1 Therapeutic drug for suppressing functions of nkt cells containing glycolipid derivative as active ingredient |
| 05/03/2007 | CA2627543A1 Implantable biocompatible immttnoisolatory vehicle for delivery of gdnf |
| 05/03/2007 | CA2627336A1 Method of modulation of mullerian inhibitory substance (mis) receptor for the treatment of neurodegenerative diseases. |
| 05/03/2007 | CA2627234A1 Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses |
| 05/03/2007 | CA2627211A1 Aminoacid derivatives containing a disulfanyl group in the form of mixed disulfanyl and aminopeptidase n inhibitors |
| 05/03/2007 | CA2627139A1 Novel benzoxathiin derivative |
| 05/03/2007 | CA2626976A1 Heterocyclic aspartyl protease inhibitors |
| 05/03/2007 | CA2626975A1 8-[bis-(2-chloro-phenyl)-methyl]-3-phenyl-8-aza-bicyclo [3.2.1] octane-3-carboxylic acid amide as ligand for the nociceptin receptor orl-1 |
| 05/03/2007 | CA2626190A1 Derivatives for modulation of ion channels |
| 05/03/2007 | CA2626180A1 Tricyclic compounds useful as oxytocin receptor agonists |
| 05/03/2007 | CA2623838A1 Extract of the family dioscoreaceae and composition for preventing or treating peripheral neuropathy comprising the same |
| 05/03/2007 | CA2623160A1 Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists |
| 05/03/2007 | CA2616416A1 Trazodone composition for once a day adminisitiation |
| 05/02/2007 | EP1780278A2 Mammalian calcium channels and related probes, cell lines and methods |
| 05/02/2007 | EP1780212A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE |
| 05/02/2007 | EP1780201A2 Phenylalanine enamide derivatives possessing a cyclobutene group, for use as integrin inhibitors |
| 05/02/2007 | EP1780196A2 Pyridine derivatives for use as vanilloid receptor ligands |
| 05/02/2007 | EP1779867A1 Nerve reveneration promoter |
| 05/02/2007 | EP1779858A1 Use of selenium compounds, especially selenium yeasts for altering cognitive function |
| 05/02/2007 | EP1779856A1 Use of selenium compounds, especially selenium yeasts in the treatment of Alzheimer, neurodegenerative diseases and diabetes |
| 05/02/2007 | EP1778687A2 Fused ring heterocycle kinase modulators |
| 05/02/2007 | EP1778684A1 4-PIPERAZINYL-PYRIMIDINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D<sb>3</sb> RECEPTOR |
| 05/02/2007 | EP1778682A1 Heterocyclic compounds useful as dpp- iv inhibitors |
| 05/02/2007 | EP1778658A2 Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof |
| 05/02/2007 | EP1778643A1 Tetrahydrobenzazepines as antagonists and/or reverse agonists of the histamine h3 receptor |
| 05/02/2007 | EP1778642A1 5-ht7 receptor antagonosts |
| 05/02/2007 | EP1778641A1 5-ht7 receptor antagonists |
| 05/02/2007 | EP1778637A2 Fkbp binding composition and pharmaceutical use thereof |
| 05/02/2007 | EP1778623A2 Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases |
| 05/02/2007 | EP1778619A2 T type calcium channel inhibitors |
| 05/02/2007 | EP1778287A2 Combination therapy with nk3 receptor antagonists for the treatment of schizophrenia |
| 05/02/2007 | EP1778286A2 Combination therapy with glatiramer acetate and riluzole |
| 05/02/2007 | EP1778279A1 Pharmaceutical composition containing botulinum neurotoxin a2 |
| 05/02/2007 | EP1778273A2 Promotion of axonal regeneration |
| 05/02/2007 | EP1778267A2 Compositions and methods related to heart failure |
| 05/02/2007 | EP1778256A1 Use of xenon as neuroprotectant in a neonatal subject |
| 05/02/2007 | EP1778253A1 Glycosylphosphatidylinositol glycan signalling via integrins functioning as glycan specific receptors |
| 05/02/2007 | EP1778246A2 Pharmaceutical composition comprising polymorphic forms of dehydroepiandrosterone |
| 05/02/2007 | EP1778245A2 T type calcium channel blockers and the treatment of diseases |
| 05/02/2007 | EP1778244A1 Use of n-desmethylclozapine to treat human neuropsychiatric disease |
| 05/02/2007 | EP1778243A2 Substituted azepine derivatives as serotonin receptor modulators |
| 05/02/2007 | EP1778241A1 Combination of a selective noradrenaline reuptake inhibitor and a pdev inhibitor |
| 05/02/2007 | EP1778236A1 Modified pyrimidine glucocorticoid receptor modulators |
| 05/02/2007 | EP1778225A2 Pyrrolo(oxo)isoquinolines as 5ht ligands |